Part VI: Summary of the risk management plan

Summary of risk management plan for Enkia (rivaroxaban)

This is a summary of the risk management plan (RMP) for Enkia. The RMP details important risks of Enkia, how these risks can be minimised, and how more information will be obtained about Enkia's risks and uncertainties (missing information).

Enkia's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Enkia should be used.

Important new concerns or changes to the current ones will be included in updates of Enkia's RMP.

I. The medicine and what it is used for

Enkia is authorised for

- Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
- Co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
- Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
- Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

(see SmPC for the full indication)

It contains rivaroxaban as the active substance and it is given by oral administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Enkia, together with measures to minimise such risks and the proposed studies for learning more about Enkia's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g., with prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Enkia, these measures are supplemented with *additional risk minimisation measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Enkia is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Enkia are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Enkia. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	Haemorrhage
Important potential risks	Embryo-foetal toxicity
Missing information	Remedial pro-coagulant therapy for excessive haemorrhage Patients with atrial fibrillation (AF) and a prosthetic heart valve

II.B Summary of important risks

Important identified risk: *Haemorrhage*	
Risk minimisation measures	Routine risk minimisation measures: *SmPC sections 4.3, 4.4 and 4.8. PL sections 2 and 4.* *Pack size: Limited pack sizes* *Legal status: Prescription-only medicine*

Important identified risk: *Haemorrhage*	
	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: *None* Additional risk minimisation measures: *Healthcare Professional Guide* *Patient alert card*

Important potential risk: *Embryo-foetal toxicity*	
Risk minimisation measures	Routine risk minimisation measures: *SmPC sections 4.3, 4.6 and 5.3. PL section 2.* *Pack size: Limited pack sizes* *Legal status: Prescription-only medicine* Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: *None*

Missing information: *Remedial pro-coagulant therapy for excessive haemorrhage*	
Risk minimisation measures	Routine risk minimisation measures: *SmPC section 4.9. PL section 3.* *Pack size: Limited pack sizes* *Legal status: Prescription-only medicine* Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: *None*

Missing information: *Patients with atrial fibrillation (AF) and a prosthetic heart valve*	
Risk minimisation measures	Routine risk minimisation measures: *SmPC section 4.4. PL section 2.* *Pack size: Limited pack sizes* *Legal status: Prescription-only medicine* Routine risk minimisation activities recommending specific clinical measures to address the risk: *None*

Missing information: ***Patients with atrial fibrillation (AF) and a prosthetic heart valve***	
	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: *None*

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Enkia.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Enkia.